0001607062-19-000173.txt : 20190709 0001607062-19-000173.hdr.sgml : 20190709 20190425111800 ACCESSION NUMBER: 0001607062-19-000173 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 10102 USA TODAY WAY CITY: MIRAMAR STATE: FL ZIP: 33025 BUSINESS PHONE: 416-364-2551 MAIL ADDRESS: STREET 1: 10102 USA TODAY WAY CITY: MIRAMAR STATE: FL ZIP: 33025 CORRESP 1 filename1.htm

 

 

Gary A. Miller

215.851.8472

gmiller@eckertseamans.com 

 

April 25, 2019

 

 

Securities and Exchange Commission

Division of Corporation Finance

Office of Healthcare & Insurance

100 S Street, NE

Washington, DC 20549-0213

Attn: Keira Nakada

Attn: Sharon Blume

 

 

Re: Generex Biotechnology Corp.

Form 10-K for the Fiscal Year Ended July 31, 2018

Filed October 26, 2018

Form 8-K/A Dated October 3, 2018

Filed December 19, 2018

File № 000-25169

 

Mses. Nakada and Blume:

 

This is a supplemental response to the Staff’s first comment contained in your correspondence dated 1 March 2019.

 

Please find the issuer’s supplemental response below, restating the Commission’s comments in bold, and the company’s response in plain text.

 

1.Report of Independent Accountants, page 3 - We note your auditor’s reference to a predecessor auditor for the fiscal year ended December 31, 2016. Please provide the signed audit report of the predecessor auditor referenced therein as required under Article 2 of Regulation S-X or tell us why such report is not required. If you are unable to obtain a reissued audit report, you must engage another accountant to reaudit the financial statements.

 

Answer

 

On April 24, 2019, Generex submitted to the office of the Chief Accountant, Division of Corporate Finance, a request for waiver of the requirement to file the audited financial statements of the business acquired for the fiscal year ended December 31, 2016. We will submit a subsequent response to this comment promptly upon receiving a final disposition of that request.

 

Thank you for your attention and patience.

 

/s/ Gary A. Miller

 

Sincerely yours,

 

Gary A. Miller

 

 

 

GAM:ncd

Cc: Joseph Moscato, Chief Executive Officer

Mark Corrao, Chief Financial Officer

Marshal Shichtman, Esq.